Jiangsu Sihuan Bioengineering Co., Ltd. engages in the pharmaceutical business in China. It offers delusen, an anti-tumor biotherapeutic drug for the treatment of kidney cancer, malignant melanoma, and cancerous chest and abdominal mass; Xinde Lusheng; Xin Lisheng; and Ring BO. It also engages in breeding and sales of flowers and seedlings; and landscaping projects. Jiangsu Sihuan Bioengineering Co., Ltd. was founded in 1992 and is headquartered in Jiangyin, China.
Stock data | 2025 | Change |
---|---|---|
Price | $0.42626096491228066 | N/A |
Market Cap | $438.86M | N/A |
Shares Outstanding | 1.03B | N/A |
Employees | 250.00 | N/A |
Valuation | 2025 | Change |
---|---|---|
P/FCF | 3750.97 | N/A |
Dividends | 2025 | Change |
---|---|---|
Dividend Yield | 0.02% | N/A |
Dividend per share | 0.0001 | N/A |
Growth | 2025 | Change |
---|---|---|
CAPEX | 880.09K | N/A |
Earnings | 2025 | Change |
---|---|---|
Free Cash Flow | $117.00K | N/A |